as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹3,140.2
Change
+7.5 (0.24%)
Open
₹3,120.2
Prev. Close
₹3,132.7
Day High
₹3,175.0
Day Low
₹3,120.2
Volume Analysis
Traded
13,319
Delivered
4,113
Delivery %
30.88%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (47.1%)
- •Strong operating margin (24.0%)
Weaknesses (1)
- •Trading within 3% of its 52-week low (₹3049.0)
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹3,224.86 | ₹3,199.93 | ₹3,170.06 | ₹3,145.13 | ₹3,115.26 | ₹3,090.33 | ₹3,060.46 |
| Fibonacci | ₹3,199.93 | ₹3,179.0 | ₹3,166.06 | ₹3,145.13 | ₹3,124.2 | ₹3,111.26 | ₹3,090.33 |
| Camarilla | ₹3,155.27 | ₹3,150.25 | ₹3,145.22 | ₹3,145.13 | ₹3,135.18 | ₹3,130.15 | ₹3,125.13 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-23.37%
1 Week
+2.04%
1 Month
-1.3%
3 Months
-7.81%
6 Months
-3.75%
1 Year
-33.87%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹1,229.71
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
47.97%
Net margin 20.52% × asset turnover 1.25x × equity multiplier 1.87x
Company Overview
Sector
Healthcare
Market Cap
₹7,232 Cr
P/E (TTM)
16.4
ROE
47.1%
Book Value
₹374.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.
TopFund Analysis
Sanofi India Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Momentum (5/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (47.1%); strong operating margin (24.0%); trading within 3% of its 52-week low (₹3049.0). FII holding has been falling.
TopFund Score — Fundamentals Quality
66/100 — GoodData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company's working capital requirements have reduced from 27.6 days to 20.4 days
- −Stock is trading at 8.39 times its book value
- −Debtor days have increased from 32.9 to 41.7 days.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Sanofi India received GST show cause notice for alleged excess ITC; demand totals Rs.23.74 crore.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales + | 515 | 491 | 469 | 511 | 464 | 524 | 515 |
| Expenses + | 393 | 377 | 370 | 374 | 348 | 404 | 397 |
| Operating Profit | 122 | 114 | 100 | 137 | 116 | 120 | 118 |
| OPM % | 24.0% | 23.0% | 21.0% | 27.0% | 25.0% | 23.0% | 23.0% |
| Other Income + | 57 | 82 | 77 | 41 | 21 | 2 | 14 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 10 |
| Profit before tax | 169 | 186 | 167 | 169 | 127 | 113 | 122 |
| Tax % | 27.0% | 18.0% | 18.0% | 19.0% | 19.0% | 27.0% | 25.0% |
| Net Profit + | 123 | 152 | 138 | 137 | 103 | 82 | 91 |
| EPS in Rs | 53 | 66 | 60 | 59 | 45 | 36 | 40 |
| Raw PDF | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Sales + | 1,996 | 2,013 |
| Expenses + | 1,508 | 1,522 |
| Operating Profit | 488 | 491 |
| OPM % | 24.0% | 24.0% |
| Other Income + | 317 | 78 |
| Interest | 2 | 2 |
| Depreciation | 36 | 37 |
| Profit before tax | 767 | 531 |
| Tax % | 21.0% | 22.0% |
| Net Profit + | 603 | 413 |
| EPS in Rs | 262 | 180 |
| Dividend Payout % | 64.0% | 65.0% |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Reserves | 992 | 838 |
| Borrowings + | 19 | 19 |
| Other Liabilities + | 681 | 732 |
| Total Liabilities | 1,715 | 1,612 |
| Fixed Assets + | 315 | 312 |
| CWIP | 16 | 18 |
| Investments | 0 | 0 |
| Other Assets + | 1,384 | 1,281 |
| Total Assets | 1,715 | 1,612 |
| Equity Capital | 23 | 23 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Cash from Operating Activity + | 230 | 462 |
| Cash from Investing Activity + | 38 | -180 |
| Cash from Financing Activity + | -878 | -392 |
| Net Cash Flow | -610 | -111 |
| CFO/OP | 97 | 114 |
| Free Cash Flow | 220 | 426 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 11.1% | 10.78% | 10.61% | 11.21% | 11.2% | 11.04% | 11.01% | 10.94% | 11.75% | 12.75% | 12.84% | 14.05% |
| Promoters | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% | 60.4% |
| FII | 6.8% | 6.31% | 6.11% | 5.81% | 5.78% | 5.64% | 5.58% | 5.61% | 5.57% | 5.55% | 5.65% | 5.69% |
| DII | 21.68% | 22.51% | 22.88% | 22.6% | 22.62% | 22.94% | 23.02% | 23.06% | 22.28% | 21.3% | 21.12% | 19.87% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Sanofi India Limited (this stock) | 7,232 | 16.4 | 8.4 | 47.1% |
| Innova Captab Limited | 7,402 | 48.1 | 6.78 | 13.7% |
| Nephrocare Health Serv L | 7,005 | 82.3 | 6.28 | 8.83% |
| Bliss Gvs Pharma Ltd | 7,486 | 54.4 | 6.23 | 11.8% |
| Sun Pharma Adv.res.co.ltd | 6,784 | 4.25 | 5.06 | 279.0% |
| Kovai Medical Center & Ho | 6,653 | 115.0 | 23.07 | 22.2% |
| Morepen Lab. Ltd | 6,596 | 56.2 | 5.26 | 5.33% |
Which Mutual Funds Hold Sanofi India Limited?
Frequently Asked Questions about Sanofi India Limited
Sanofi India Limited (SANOFI) closed at ₹3,140.2 on NSE on 25 September 2026, up 7.5 (0.24%) from the previous close.
Sanofi India Limited trades on the NSE (National Stock Exchange of India) under the symbol SANOFI.
Sanofi India Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 16.4.
Sanofi India Limited has a dividend yield of 2.39%.
Sanofi India Limited's 52-week high is ₹4,898.0 and its 52-week low is ₹3,049.0.
Sanofi India Limited has a market capitalisation of ₹7,232 crore.
Sanofi India Limited has a TopFund Quality Score of 66/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Sanofi India Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.